Salim Yazji

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu et al. · Clinical Cancer Research · 2008 · 158 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

José Rodríguez, Mark F. Munsell, Salim Yazji et al. · Journal of Clinical Oncology · 2001 · 155 citations

Medicine, Oncology, Chemotherapy +13

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Peter Reichardt, Jean‐Yves Blay, Hans Gelderblom et al. · Annals of Oncology · 2012 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Lee S. Rosen, Patricia LoRusso, Wen Wee et al. · Investigational New Drugs · 2016 · 84 citations

Medicine, Oncology, Pharmacology +9

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

Salim Yazji, Francis J. Giles, Elihu H. Estey et al. · Leukemia · 2003 · 79 citations

Medicine, Hematology, Pharmacotherapy +10